Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
Japan's Health, Labor and Welfare Ministry announced conditional approval on March 6, 2026, for two regenerative medicine products using induced pluripotent stem (iPS) cells, building on the expert panel's endorsement reported earlier (see prior article in this series for trial details, background, and Shinya Yamanaka's reaction).
Cuorips Inc., an Osaka University startup, developed ReHeart (also stylized RiHEART) for severe heart failure due to ischemic cardiomyopathy. iPS-derived cardiomyocytes are formed into sheets attached to the heart surface to regenerate blood vessels and improve function. Sales are targeted for autumn 2026.
Sumitomo Pharma Co.'s Amchepry treats Parkinson's disease by transplanting iPS-derived dopamine-producing nerve cells into the brain, aiming to alleviate motor symptoms like tremors and gait issues. Commercial rollout is planned between summer and autumn 2026.
These approvals represent a pivotal step in bringing iPS technology—pioneered by Nobel laureate Yamanaka—to widespread clinical use, pending final pricing and insurance deliberations.
